Combination lipid therapy in type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Combination lipid therapy in type 2 diabetes.

Combination lipid therapy in type 2 diabetes.

http://www.wikidata.org/entity/Q42906945

about

Q42940578 Q45608372

sameAs

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Hypertriglyceridemia and Cardiovascular Diseases: Revisited Residual macrovascular risk in 2013: what have we learned?Treatment of dyslipidemia Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Consensus statement on management of dyslipidemia in Indian subjects.Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study.Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy The role of triglycerides in atherosclerosis.Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial Triglyceride and cardiovascular risk: A critical appraisal.Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.Combination lipid therapy in type 2 diabetes mellitus.Safety review of combination drugs for hyperlipidemia.Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists Demystifying the management of hypertriglyceridaemia.Saroglitazar for the treatment of dyslipidemia in diabetic patients.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Statin combination therapy and cardiovascular risk reduction.

P2860

Q21246041-A2777588-CBC2-46F0-9459-95F2C0000602 Q24564203-B29E4676-4954-4413-8FF6-2F8C6AA1E93D Q26750954-BD994D45-C512-4E0F-8CA7-F04DF9D29942 Q26996039-848191A4-D0FC-44E2-A405-FA4FF545F097 Q27026114-77B1373C-2058-4D54-9620-E3B15BD6D869 Q28548389-6A10AD17-C490-44F9-A432-6C8B55E7482A Q30048180-573BC7A2-CCBB-4261-8A2A-ABB30CCD6274 Q30357715-C7AB6963-8831-4B24-A0DA-3814C63B3F94 Q33646780-A77CFEDA-FE73-4816-8A73-5EE854F2D37B Q33776187-07959958-26E5-4811-9960-E6AEEDE118A2 Q33776214-BE7C3CBB-E39D-4C4A-8580-C66D6813CC27 Q34181381-566B9EE6-39C5-411E-A057-7EF84ABF8B4F Q34241802-6B187B6E-9CE9-4732-8C57-9BB2BA0A5CDE Q34359967-F6F71A3F-5653-4A68-AED0-44A3CCAF3FFA Q34469183-E699BAB8-7826-406B-BA8E-FD36D2FC4E96 Q34687470-7AC0B6E7-F970-4427-967C-E6B5124E5C38 Q34980772-E2E9B6C5-2278-4660-A1D2-990E8A999A85 Q35130613-684B4526-A2DE-42DF-8DBB-D82E7DAB7711 Q35595619-36D705B8-3E1B-4EB5-A9F5-2F7EF5C6A342 Q35602424-96EA3DFF-0104-4643-96F3-B604B3667C5D Q35650429-A96D06C7-16AB-430C-A89D-F4C24C7743A7 Q36124203-9E6C8317-0B56-4F60-9F21-D8DF11ED26F4 Q36443768-67722247-126F-4534-81E7-FBC2BA07B5A4 Q36489752-59C0D752-C327-4EF2-BF8F-398A39FFD2DF Q37015549-F955514B-2C2E-4F38-8567-610938581C88 Q37119482-B03804CF-748D-414C-94EF-CA86F57D8B62 Q37129540-3AEF8DEE-D97E-4869-8926-A09EC02C5FC0 Q37254899-1A3B09F0-87CC-4F60-996B-BB496A87FA30 Q37811855-C259B8FF-15D3-4045-AB79-A1203156A3AB Q37842472-0D104F18-5FBF-42A2-9ED8-BCEAF0002030 Q37854747-B5D321ED-465C-4B95-97D9-498FE25FCEA1 Q37855939-5F7E63E3-3AD9-4F3A-A9B6-9121E85BA49F Q37898699-4540AB6D-0C9A-4160-AE29-E8C9649BD71E Q38014975-81A8782A-0CB3-463D-9351-977A74D9FB97 Q38039980-AAEF7A9E-4D7B-4631-A3F1-D943A954A7DE Q38110581-2C466D72-E8F6-4D11-9219-CC7E00310C5B Q38141575-B9FA92EE-91B0-449D-BB50-35D00BDA44EF Q38352759-F6C9E091-8963-4427-BF8B-5B84A6A36995 Q38546242-C6D117BF-DAE7-42BC-9EC0-8C9BAC40E1D0 Q38881156-D16C5B18-2D33-46E0-874F-A349A99077A6

P2860

Combination lipid therapy in type 2 diabetes.

http://www.wikidata.org/entity/Q42906945

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Combination lipid therapy in type 2 diabetes.

@en

Combination lipid therapy in type 2 diabetes.

@nl

type

label

Combination lipid therapy in type 2 diabetes.

@en

Combination lipid therapy in type 2 diabetes.

@nl

prefLabel

Combination lipid therapy in type 2 diabetes.

@en

Combination lipid therapy in type 2 diabetes.

@nl

P1433

Q42906945-A24075B2-6BDB-4E02-AF63-E194A764A534

P1476

Q42906945-879F703D-4BA3-4C0B-A7C1-8C9DF8CA2CD5

P2093

Q42906945-18081B61-273B-4BF4-AA1C-D2C849F8C08E

Q42906945-6DC59732-5D89-4280-9C76-8582DDE2E541

Q42906945-8C75535A-DCB6-42BF-BA86-37B63218F02D

Q42906945-B50CD846-2E62-468C-8ACF-5688DD8ED688

Q42906945-DB88C747-7ADA-473C-8DA1-E6BA8F18EA1C

Q42906945-E269C1CC-3642-4409-85B0-AAAD2B9BDA3E

Q42906945-FD77CD16-2080-4EF8-BC93-A66EC651D1E3

P304

Q42906945-2D7E24EE-AEC5-4EA7-9A7D-30867ADE664E

Q42906945-C40569CE-A2F6-4753-A95D-6F15D54947FB

Q42906945-F2010B3B-4CB4-49AC-866F-0014B04B543D

P31

Q42906945-6198C202-4637-406A-B8C8-D7901BA94F0F

P356

Q42906945-3CA80D58-4504-4BC4-A828-7E8BF7D037B7

P407

Q42906945-16AE5A07-C647-4CE7-80E6-552BC27F69E4

P433

Q42906945-DCF26E62-EDBB-4A3B-82B5-7B8710E9FFDD

P478

Q42906945-453E624C-C1D2-41CA-BEB3-0CAEB691C54F

P577

Q42906945-D0298900-18DD-4B9A-A0A8-44E867ECE2E1

P698

Q42906945-1009CDE3-5017-4452-A310-89FC405E5EF9

Q42906945-14D3D30A-FE3E-4C9F-BE7E-FC7732C49F25

Q42906945-47CE8B1C-E1C6-4C9A-AC5E-9B26CD069426

P921

Q42906945-524A450E-320D-43D0-A3FA-D1558549ED8B

P356

P1433

The New England Journal of Medicine

P1476

Combination lipid therapy in type 2 diabetes.

@en

P2093

Christoph H Saely

http://www.w3.org/2001/XMLSchema#string

Frank M Sacks

http://www.w3.org/2001/XMLSchema#string

Heinz Drexel

http://www.w3.org/2001/XMLSchema#string

Jean-Charles Fruchart

http://www.w3.org/2001/XMLSchema#string

Philipp Rein

http://www.w3.org/2001/XMLSchema#string

Vincent J Carey

http://www.w3.org/2001/XMLSchema#string

William J Perkins

http://www.w3.org/2001/XMLSchema#string

P304

692-4; author reply 694-5

http://www.w3.org/2001/XMLSchema#string

692; author reply 694-5

http://www.w3.org/2001/XMLSchema#string

694; author reply 694-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMC1006407

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20701533

http://www.w3.org/2001/XMLSchema#string

20842772

http://www.w3.org/2001/XMLSchema#string

20842773

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes